Franklin Resources
NMRA icon

Franklin Resources’s Neumora Therapeutics NMRA Stock Holding History

Franklin Resources’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-511,084
Closed -$997K – 3294
2026
Q1 		$997K Buy
+511,084
New +$1.32M ﹤0.01% 2177
2025
Q1 		– Sell
-31,357
Closed -$332K – 3040
2024
Q4 		$332K Sell
31,357
-44,345
-59% -$531K ﹤0.01% 2469
2024
Q3 		$1.18M Sell
75,702
-12,241
-14% -$143K ﹤0.01% 1919
2024
Q2 		$864K Buy
+87,943
New +$910K ﹤0.01% 1990

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Franklin Resources's NMRA Position: Q2 2026 in Review

Franklin Resources sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 511,084 shares — an estimated $997K sold.

Franklin Resources first reported a position in NMRA in Q2 2024 and held it in 4 quarters. The position peaked at $1.18M in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Franklin Resources reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Franklin Resources sold 511,084 Neumora Therapeutics shares in Q2 2026, an estimated $997K.
  • Franklin Resources first reported a position in Neumora Therapeutics in Q2 2024 and held it in 4 quarters.
  • Franklin Resources's Neumora Therapeutics position peaked at $1.18M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.